Skip to main content
Top
Published in: Diabetologia 11/2012

01-11-2012 | Article

The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes

Authors: M. Lind, M. Olsson, A. Rosengren, A.-M. Svensson, I. Bounias, S. Gudbjörnsdottir

Published in: Diabetologia | Issue 11/2012

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to examine the relationship between glycaemic control and hospitalisation for heart failure in patients with type 2 diabetes.

Methods

Patients included in the Swedish National Diabetes Register (NDR) during 1998–2003 were followed until hospitalisation for heart failure, death or 31 December 2009. Unadjusted and adjusted incidence rates for heart failure were estimated by Poisson regression and relative risk was estimated by Cox regression.

Results

In 83,021 patients with type 2 diabetes, 10,969 (13.2%) were hospitalised with a primary or secondary diagnosis of heart failure during a mean follow-up of 7.2 years. The incidence increased by male sex (p < 0.001), older age (p < 0.001) and longer diabetes duration (p < 0.001). In Cox regression adjusting for risk factors of heart failure the HR per each percentage unit higher HbA1c (10 mmol/mol) for heart-failure hospitalisation was 1.12 (95% CI 1.10, 1.14). By category of HbA1c the HR for heart failure hospitalisation was: HbA1c 6.0 to <7.0% (42 to <53 mmol/mol), 0.91 (95% CI 0.84, 0.98); HbA1c 7.0 to <8.0% (53 to <64 mmol/mol), 0.99 (95% CI 0.91, 1.07); HbA1c 8.0 to <9.0% (64 to <75 mmol/mol), 1.10 (95% CI 1.01, 1.20); HbA1c 9.0 to <10.0% (75 to <86 mmol/mol), 1.27 (95% CI 1.15, 1.41); HbA1c ≥10.0 % (≥86 mmol/mol), 1.71 (1.51, 1.93) (reference HbA1c <6% [42 mmol/mol]). The HR for patients with HbA1c 7.0 to <8.0% (53 to <64 mmol/mol) compared with patients with HbA1c 6.0 to <7.0% (42 to <53 mmol/mol) was 1.09 (95% CI 1.03, 1.14).

Conclusions/interpretation

Poor glycaemic control (HbA1c >7% [53 mmol/mol]) is associated with an increased risk of hospitalisation for heart failure in patients with type 2 diabetes.
Literature
1.
go back to reference UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
2.
go back to reference Mulnier HE, Seaman HE, Raleigh VS, Soe-damah-Muthu SS, Colhoun HM, Lawrenson RA (2006) Mortality in people with type 2 diabetes in the UK. Diabet Med 23:516–521PubMedCrossRef Mulnier HE, Seaman HE, Raleigh VS, Soe-damah-Muthu SS, Colhoun HM, Lawrenson RA (2006) Mortality in people with type 2 diabetes in the UK. Diabet Med 23:516–521PubMedCrossRef
3.
go back to reference Seshasai SR, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841PubMedCrossRef Seshasai SR, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841PubMedCrossRef
4.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589PubMedCrossRef
5.
go back to reference Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef
6.
go back to reference UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317:703–713CrossRef UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317:703–713CrossRef
7.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125:e2–e220PubMedCrossRef Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125:e2–e220PubMedCrossRef
8.
go back to reference Rydén-Bergsten T, Andersson F (1999) The health care costs of heart failure in Sweden. J Intern Med 246:275–284PubMedCrossRef Rydén-Bergsten T, Andersson F (1999) The health care costs of heart failure in Sweden. J Intern Med 246:275–284PubMedCrossRef
9.
go back to reference Turnbull F, Abraira C, Anderson R et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298PubMedCrossRef Turnbull F, Abraira C, Anderson R et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298PubMedCrossRef
10.
go back to reference Eeg-Olofsson K, Cederholm J, Nilsson PM et al (2010) New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 268:471–482PubMedCrossRef Eeg-Olofsson K, Cederholm J, Nilsson PM et al (2010) New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 268:471–482PubMedCrossRef
11.
go back to reference Shafazand M (2009) Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J 30:671–678PubMedCrossRef Shafazand M (2009) Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J 30:671–678PubMedCrossRef
13.
go back to reference Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A (2011) Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378:140–146PubMedCrossRef Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A (2011) Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378:140–146PubMedCrossRef
14.
go back to reference Hoelzel W, Weykamp C, Jeppsson JO et al (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50:166–174PubMedCrossRef Hoelzel W, Weykamp C, Jeppsson JO et al (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50:166–174PubMedCrossRef
15.
go back to reference Ingelsson E, Arnlöv J, Sundström J, Lind L (2005) The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 7:787–791PubMedCrossRef Ingelsson E, Arnlöv J, Sundström J, Lind L (2005) The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 7:787–791PubMedCrossRef
16.
go back to reference Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef
17.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMedCrossRef
18.
go back to reference Iribarren C, Karter AJ, Go AS et al (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668–2673PubMedCrossRef Iribarren C, Karter AJ, Go AS et al (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668–2673PubMedCrossRef
19.
go back to reference Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884PubMedCrossRef Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884PubMedCrossRef
20.
go back to reference Lind M, Odén A, Fahlén M, Eliasson B (2009) The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLoS One 4:e4412PubMedCrossRef Lind M, Odén A, Fahlén M, Eliasson B (2009) The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLoS One 4:e4412PubMedCrossRef
21.
go back to reference Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489PubMedCrossRef Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489PubMedCrossRef
22.
go back to reference Aguilar D, Bozkurt B, Ramasubbu K, Deswal A (2009) Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 54:422–428PubMedCrossRef Aguilar D, Bozkurt B, Ramasubbu K, Deswal A (2009) Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 54:422–428PubMedCrossRef
23.
go back to reference Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559PubMedCrossRef
24.
go back to reference Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53:298–304PubMedCrossRef Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53:298–304PubMedCrossRef
25.
go back to reference Riddle MC (2010) Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 122:844–846PubMedCrossRef Riddle MC (2010) Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 122:844–846PubMedCrossRef
26.
go back to reference ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood-glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood-glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef
Metadata
Title
The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes
Authors
M. Lind
M. Olsson
A. Rosengren
A.-M. Svensson
I. Bounias
S. Gudbjörnsdottir
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2681-3

Other articles of this Issue 11/2012

Diabetologia 11/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.